Incidence and risk factors of Trimethoprim/Sulfamethoxazole associated hyperkalemia in Pneumocystis jirovecii Pneumonia patients
Article Sidebar
Main Article Content
Abstract
This study was descriptive and case-control study with sampling of patients diagnosed with Pneumocystis jirovecii pneumonia (PJP) who received trimethoprim/sulfamethoxazole (TMP/SMX) treatment. Data were collected between during January 1, 2012 - May 31, 2022. The objective of study was to determine incidence and risk factor of hyperkalemia in PJP patients who received TMP/SMX treatment in Pathumthani Hospital. Statistical analyses were conducted to examine factor association of hyperkalemia by odds ratio (OR), adjusted odds ratio (ORAdj) and confidence interval (95%CI) hypothesis prove with p-value < 0.05. The result of study was found 76 PJP patients which met criteria. The incidence of hyperkalemia in PJP Patients who receiving TMP/SMX patient is 14 cases (18.4%) and 2 patients (1.6%) had severe hyperkalemia. Risk factor associated with hyperkalemia is low BMI < 18.5 kg/m2 (p=0.01) ORadj 4.912 (95% CI 1.281 – 18.831). PJP patients who received TMP/SMX especially malnutrition patients should be monitored of serum potassium for early detection of hyperkalemia.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Opportunistic Infections: prophylaxis and treatment in: Ruxrungtham K, Chokephaibulkit K, Chetchotisakd P, Chariyalertsak S, Kiertburanakul S, Putacharoen O, et al, editors. Thailand national guidelines on HIV/AIDS treatment and prevention 2021/2022. Nonthaburi: Division of AIDS and STIs, Department of Disease Control; 2022. p. 181-3.
American pharmacists association. Drug information handbook: with international trade names index. 25th ed. Hudson, Ohio: Lexi-Comp; 2016. p. 1358.
BACTRIM (sulfamethoxazole and trimethoprim) [Package insert]. Cranbury (NJ): Sun Pharmaceutical Industries; 1981.
Eiam-Ong S, Kurtzman NA, Sabatini S. Studies on the mechanism of trimethoprim-induced hyperkalemia. Kidney Int. 1996;49(5):1372-8.
Velázquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119(4):296-301.
Witt JM, Koo JM, Danielson BD. Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men. Ann Pharmacother. 1996;30(4):347-50.
Marinella MA. Trimethoprim-induced hyperkalemia: An analysis of reported cases. Gerontology. 1999;45(4):209-12.
Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D'Andrea D, Szerlip H, Kleyman TR. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med. 1993;328(10):703-6.
Plantaz MMEA, Veldman BAJ, Esselink AC, Fleuren HWHA, Kramers C. Co-trimoxazole induced hyperkalemia and potassium monitoring in hospitalized patients. Int J Clin Pharm. 2020;42(6):1405-11.
Al AdAwi RM, Albu-Mahmood Z, Abdelgelil M, Abdelaziz H, Stewart D, Awaisu A. Incidence of Co-Trimoxazole-Induced Hyperkalemia in a Tertiary Care Hospital. Risk Manag Healthc Policy. 2021;14:519-25.
Mengi T, Ozkok H, Comert B. Evaluation of Hyperkalemia Associated with TrimethoprimSulfamethoxazole in the Intensive Care Unit. J Crit Intensive Care. 2021;12:27-31.
Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med. 2010;170(12):1045-9.
Fralick M, Macdonald EM, Gomes T, Antoniou T, Hollands S, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ. 2014;349:g6196.
Weir MA, Juurlink DN, Gomes T, Mamdani M, Hackam DG, Jain AK, Garg AX. Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study. Clin J Am Soc Nephrol. 2010;5(9):1544-51.
Kennard A, Roberts DM. Medicinal mishap: Trimethoprim-induced critical hyperkalaemia. Aust Prescr. 2016;39(4):136-7.
Diribe N, Le J. Trimethoprim/Sulfamethoxazole-Induced Bradycardia, Renal Failure, AV-Node Blockers, Shock and Hyperkalemia Syndrome. Clin Pract Cases Emerg Med. 2019;3(3):282-5.